Qiming Venture Partners

Name

Qiming Venture Partners

Legal name

Qiming Weichuang Venture Capital Management (Beijing) Co., Ltd. (启明维创创业投资管理（北京）有限公司)

Website

https://qimingvc.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Venture Capital

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro industry

PRIMARYFSANAAAD

Sector-Focused Venture Capital (Vertical Specialists)

Financial & Insurance/Private Equity & Venture Capital/Venture Capital Firms

Keywords

• Venture capital investing
• Technology sector investment
• Healthcare venture capital
• Early stage funding
• Growth stage investment

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Management Fees: Qiming Venture Partners generates revenue primarily through management fees on its 11 USD funds and 7 RMB funds, totaling $9.5 billion in AUM (as of August 2024). This represents a standard asset management fee structure.
2. Carried Interest from Exits: Qiming generates carried interest through 70+ IPOs and 140+ M&A and other exits. Portfolio exits span US (NYSE, NASDAQ), Hong Kong Stock Exchange, Shanghai Stock Exchange, and Shenzhen Stock Exchange, including companies such as Xiaomi, Meituan, Bilibili, Zhihu, and more.

Go-to-market motion3 records

Core offering

Qiming Venture Partners is a private venture capital firm that raises and manages investment funds (11 USD funds and 7 RMB funds totaling US$9.5 billion in AUM as of August 2024) and deploys that capital into early- and growth-stage startups in Technology and Healthcare sectors. The firm provides portfolio companies with capital, strategic guidance, industry resources, and post-investment ecosystem support. It generates returns through management fees and carried interest from exits via IPOs (NYSE, NASDAQ, HKEX, SSE, SZSE) and M&A transactions.

Product overview

Qiming Venture Partners (启明创投) operates a single integrated venture capital platform rather than a software product portfolio: it is a single firm-wide investment business composed of multiple fund vehicles (11 USD funds and 7 RMB funds) that deploy capital across two main investment verticals — Technology and Healthcare Innovation. The Technology vertical covers TMT, AI, robotics, semiconductors, enterprise services, blockchain, mobility, and consumer internet; the Healthcare Innovation vertical covers innovative drugs, diagnostics, medical devices, medical services, and AI/digital health. Layered on top of the core fund products are add-on services — a portfolio value-add / ecosystem program, the S2S China Symposium co-hosted with RA Capital Management (first edition scheduled October 15, 2026 in Hangzhou), the Healthcare PhD Summer Internship Program (2026 cohort announced May 2026), and ESG initiatives such as the China Rural Revitalization Entrepreneurs Support Program. As of August 2024 the firm managed US$9.5 billion in AUM, had invested in 580+ portfolio companies, recorded 70+ IPOs and 140+ M&A or other exits, and counted among its investments Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI), Zhihu (NYSE:ZH), Roborock (688169.SH), Hesai (NASDAQ:HSAI), UBTech (09880.HK), WeRide (NASDAQ:WRD), Hyperstrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Z.ai/Zhipu AI (02513.HK), Tigermed (300347.SZ), ZaiLab (NASDAQ:ZLAB), and CanSino Bio (688185.SH).

Differentiator

Problem solved

Functional benefit

Products and services

• USD Funds (11 funds)
• RMB Funds (7 funds)
• Technology Sector Investing
• Healthcare Innovation Investing
• Qiming Portfolio Value-Add / Ecosystem Services

Quantifiable outcome

• 70+ portfolio company IPOs and 140+ M&A or other exits
• +4 more outcomes

Named customers23 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered flagship.

• RA Capital ManagementflagshipStrategic or Co-development Partner · 15 October 2026Co-host of the inaugural S2S China Symposium, scheduled for October 15, 2026, in Hangzhou, China. The event aims to connect top Chinese scientists with major biotech investors and accelerate biotech innovation and commercialization in China.
• XiaomiflagshipStrategic or Co-development PartnerLong-term strategic relationship; Qiming has trusted and heavily invested in the Mi Team from Xiaomi to Xiaomi Ecosystem. Lei Jun serves as Founder, Chairman & CEO. Quote from Lei Jun: 'From Xiaomi to Xiaomi Ecosystem, Qiming has always been trusting and heavily investing in the Mi Team.'
• MedtronicflagshipStrategic or Co-development PartnerStrategic investment partnership where Qiming participated as an existing investor in Pulnovo Medical's $100M strategic financing led by Medtronic in April 2026. Pulnovo and Medtronic signed a commercial agreement for global commercialization of the PADN System.
• Hong Kong Stock ExchangeflagshipOthersQiming's portfolio companies have listed extensively on the Hong Kong Stock Exchange, including LongBio Pharma (June 2026), Viewtrix (May 2026), Axera (Feb 2026), Biren Technology (Jan 2026), Z.ai (Jan 2026), Yunji Technology (Oct 2025), and Insilico Medicine (Dec 2025).
• AstraZenecaflagshipStrategic or Co-development PartnerAstraZeneca participated as existing shareholder in Syneron Bio's $150M Series B financing, co-led by Qiming in March 2026. AstraZeneca had previously signed a deal with Syneron Bio worth $75M upfront plus up to $3.4 billion in potential milestones.
• TigermedflagshipStrategic or Co-development PartnerLong-term portfolio company; Tigermed (300347.SZ, 03347.HK) is a leading clinical trial CRO. Qiming has supported Tigermed from early stages, with founder Ye Xiaoping noting: 'We have created a model for the cooperation between entrepreneurs and venture capitalists. We support each other along the way.'
• Tencent (as former employer)flagshipOthersConnection through Video Rebirth founder Liu Wei, who previously led development of Tencent's flagship AI model.
• Z.ai (Zhipu AI)flagshipStrategic or Co-development PartnerQiming co-led Z.ai's Series B1 funding in early 2022, validating China's foundational AI innovation path. Z.ai listed on HKEX on January 8, 2026, becoming the world's first listed LLM company.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• HongShan (formerly Sequoia China): Sequoia China's spin-out is the closest direct peer to Qiming — a leading China VC with comparable dual focus on TMT and healthcare, similar AUM scale, similar Series A/B concentration, and overlapping LP base. Frequent co-investor in deals like XunTu Technology.
• IDG Capital: One of the longest-established foreign-affiliated China VCs covering TMT, healthcare, and consumer at early and growth stages. Directly comparable investment mandate, fund structure, and target portfolio to Qiming.
• Matrixpartners China: US-pedigree early-stage China VC with comparable focus on technology and healthcare startups. Comparable Series A/B entry point and similar LP profile makes it one of Qiming's most direct competitors.
• Legend Capital: Beijing-headquartered early- and growth-stage VC with comparable dual focus on technology and healthcare in China. Similar fund size profile and similar sector mandate to Qiming.
• Source Code Capital: China-focused early-stage VC with TMT and consumer emphasis. Comparable Series A/B entry and overlapping target founder base with Qiming in Chinese internet/enterprise software.
• Northern Light Venture Capital: China-domiciled early- and growth-stage VC with strong TMT focus. Comparable Series A/B entry stage and overlapping portfolio characteristics with Qiming's technology investments.
• Shunwei Capital: China-focused VC with deep TMT and AI exposure. Comparable early-stage entry and increasingly comparable AI thesis to Qiming, especially in AI/consumer-internet investments.
• 5Y Capital (formerly Morningside Venture Capital): Long-established China VC with TMT and healthcare focus. Comparable fund vintage, comparable Series A/B entry stage, and overlapping LP relationships make it a structural peer to Qiming.

Broad incumbents

• Hillhouse Capital: Broader Asia-focused investment platform with TMT and healthcare exposure across public and private markets. Larger and more diversified than Qiming, but overlaps significantly on growth-stage technology and biotech deals (co-investor with Qiming in XunTu Technology).
• CDH Investments: Major Chinese alternative asset manager with both growth equity and buyout strategies. Overlaps with Qiming on healthcare and technology growth-stage deals; broader mandate and larger AUM put it in the incumbent category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights8 records

Customer concentration

• Xx.com/QimingVC
• LinkedInlinkedin.com/company/qiming-venture-partners

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1176 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Qiming Venture Partners